Open AccessSingle high-dose oral vitamin D3 treatment in New Zealand children with inflammatory bowel disease
Author(s) -
Natalie G. Martin,
Tarah Rigterink,
Mustafa Adamji,
Catherine Wall,
Andrew S. Day
Publication year - 2019
Publication title -
translational pediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.702
H-Index - 13
eISSN - 2224-4344
pISSN - 2224-4336
DOI - 10.21037/tp.2018.11.01
Subject(s) - medicine , vitamin d and neurology , inflammatory bowel disease , vitamin d deficiency , gastroenterology , vitamin , retrospective cohort study , disease
High-dose oral vitamin D (stoss) is a novel treatment in children with inflammatory bowel disease (IBD). Vitamin D supplementation may have benefits in IBD beyond bone health including reduced disease activity and improvements in inflammatory markers. The aim of this study was to retrospectively assess the efficacy, safety and impact on disease activity of single oral high-dose vitamin D3 therapy in New Zealand (NZ) children with IBD and vitamin D deficiency.